{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:00:43Z","timestamp":1774969243298,"version":"3.50.1"},"reference-count":53,"publisher":"Bentham Science Publishers Ltd.","issue":"19","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,9,13]]},"abstract":"<jats:sec><jats:title>Aim::<\/jats:title><jats:p>Pharmacologic agents with procoagulant effects and antidotes against antithrombotic drugs play an important role in the prevention and management of perioperative coagulopathic bleeding. The aim of this narrative review is knowledge transfer from new and renewed hemostatic agents to anesthesiologists and other physicians involved in perioperative medicine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods::<\/jats:title><jats:p>The literature search was performed on PubMed and the Summaries of Product Characteristics of 6 pharmacologic agents of interest: fibrinogen concentrate, vonicog alfa, susoctocog alfa, idarucizumab, andexanet alfa, and argatroban.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results and discussion: :<\/jats:title><jats:p>This review highlights renewed interest in fibrinogen concentrate, an old prohemostatic drug, in correcting hypofibrinogenemia which is a leading pathomechanism of perioperative bleeding.<\/jats:p><\/jats:sec><jats:sec><jats:title>:<\/jats:title><jats:p>This review describes clinically relevant aspects for brand new recombinant prohemostatic drugs for their use in critical clinical situations: vonicog alfa for the prevention and correction of bleeding in von Willebrand syndrome, and susoctocog alfa in acquired hemophilia A.<\/jats:p><\/jats:sec><jats:sec><jats:title>:<\/jats:title><jats:p>Clinical experience and increasing evidence broadened the field of applications of the old antithrombotic drug argatroban to heparin resistance.<\/jats:p><\/jats:sec><jats:sec><jats:title>:<\/jats:title><jats:p>New antidotes against new antithrombotic agents revolutionized the safety of chronic antithrombotic therapy in the emergency situations of acute and trauma surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>:<\/jats:title><jats:p>Information on dosing and handling of new hemostatic drugs is summarized.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion::<\/jats:title><jats:p>New and potent hemostatic agents exist for perioperative use and may enrich the armamentarium of anesthesiologists. Implementation into clinical practice requires their availability and user knowledge. Sustainability of these new drugs depends on post-licensing research, cost-effectiveness, and clinical experience.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1381612825666190708183127","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T11:40:55Z","timestamp":1562672455000},"page":"2158-2164","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["New Hemostatic Agents: Perioperative Anesthetic Considerations"],"prefix":"10.2174","volume":"25","author":[{"given":"Antonia-Therese","family":"Kietaibl","sequence":"first","affiliation":[{"name":"Vienna Medical University, Candidate of Medicine, Spitalgasse 23, 1090 Wien, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibylle","family":"Kietaibl","sequence":"additional","affiliation":[{"name":"Sigmund Freud Private University and Department of Anesthesia and Intensive Care, Evangelical Hospital Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/978-3-540-49433-1_76","author":"Kozek-Langenecker SA","year":"2007","unstructured":"Kozek-Langenecker SA; Monitoring of hemostasis in emergency medicine. Yearbook of Intensive Care and Emergency Medicine: Springer-Verlag Heidelberg 2007,847-60","journal-title":"Yearbook of Intensive Care and Emergency Medicine: Springer-Verlag Heidelberg"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/EJA.0000000000000630","volume":"34","author":"Kozek-Langenecker S.A.","year":"2017","unstructured":"Kozek-Langenecker S.A.; Ahmed A.B.; Afshari A.; Management of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology: First update 2016. Eur J Anaesthesiol 2017,34(6),332-395","journal-title":"Eur J Anaesthesiol"},{"key":"ref=3","year":"2016","unstructured":"Bundesministerium f\u00fcr Gesundheit und Frauen Qualit\u00e4tsstandard patient blood management 2016","journal-title":"Qualit\u00e4tsstandard patient blood management"},{"key":"ref=4","unstructured":"Patient Blood Management https:\/\/www. patientbloodmanagement.de\/"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/ACO.0000000000000179","volume":"28","author":"Shander A.","year":"2015","unstructured":"Shander A.; Javidroozi M.; Blood conservation strategies and the management of perioperative anaemia. Curr Opin Anaesthesiol 2015,28(3),356-363","journal-title":"Curr Opin Anaesthesiol"},{"key":"ref=6","author":"Kietaibl S.A.","year":"2018","unstructured":"Kietaibl S.A.; Uni-Med Verlag AG Bremen London Boston 1st ed 2018","journal-title":"Uni-Med Verlag AG Bremen London Boston 1st ed"},{"key":"ref=7","author":"Rossaint R.","year":"2016","unstructured":"Rossaint R.; Bouillon B.; Cerny V.; Crit Care 2016","journal-title":"Crit Care"},{"key":"ref=8","first-page":"64","author":"Schlimp C.","year":"2018","unstructured":"Schlimp C.; Kietaibl SA, Ed Uni-Med Verlag AG Bremen London Boston 2018,64-9","journal-title":"Kietaibl SA, Ed Uni-Med Verlag AG Bremen London Boston"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"R239","DOI":"10.1186\/cc10488","volume":"15","author":"Kozek-Langenecker S.","year":"2011","unstructured":"Kozek-Langenecker S.; S\u00f8rensen B.; Hess J.R.; Spahn D.R.; Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Crit Care 2011,15(5),R239","journal-title":"Crit Care"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1213\/ANE.0000000000001897","volume":"124","author":"Levy J.H.","year":"2017","unstructured":"Levy J.H.; Grottke O.; Fries D.; Kozek-Langenecker S.; Therapeutic plasma transfusion in bleeding patients: A systematic review. Anesth Analg 2017,124(4),1268-1276","journal-title":"Anesth Analg"},{"key":"ref=11","first-page":"70","author":"Lance M.","year":"2018","unstructured":"Lance M.; Kietaibl SA, Ed Uni-Med Verlag AG Bremen London Boston 2018,70-76","journal-title":"Kietaibl SA, Ed Uni-Med Verlag AG Bremen London Boston"},{"key":"ref=12","first-page":"77","author":"Ahmed A.B.","year":"2018","unstructured":"Ahmed A.B.; Nascimento B.; Kietaibl SA, Ed Uni-Med Verlag AG Bremen London Boston 2018,77-90","journal-title":"Kietaibl SA, Ed Uni-Med Verlag AG Bremen London Boston"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/trf.12431","volume":"54","author":"Levy J.H.","year":"2014","unstructured":"Levy J.H.; Welsby I.; Goodnough L.T.; Fibrinogen as a therapeutic target for bleeding: A review of critical levels and replacement therapy. Transfusion 2014,54(5),1389-1405","journal-title":"Transfusion"},{"key":"ref=14","first-page":"360","volume":"81","author":"Hiippala S.T.","year":"1995","unstructured":"Hiippala S.T.; Myllyl\u00e4 G.J.; Vahtera E.M.; Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995,81(2),360-365","journal-title":"Anesth Analg"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/1076029615601494","volume":"22","author":"Costa-Filho R.","year":"2016","unstructured":"Costa-Filho R.; Hochleitner G.; Wendt M.; Teruya A.; Spahn D.R.; Over 50 years of fibrinogen concentrate. Clin Appl Thromb Hemost 2016,22(2),109-114","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1093\/bja\/aew315","volume":"117","author":"Schenk B.","year":"2016","unstructured":"Schenk B.; Lindner A.K.; Treichl B.; Fibrinogen supplementation ex vivo increasesclot firmness comparable to platelet transfusion in thrombocytopenia. Br J Anaesth 2016,117(5),576-582","journal-title":"Br J Anaesth"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/bja\/aeu133","volume":"113","author":"Adelmann D.","year":"2014","unstructured":"Adelmann D.; Klaus D.A.; Illievich U.M.; Fibrinogen but not factor XIII deficiency is associated with bleeding after craniotomy. Br J Anaesth 2014,113(4),628-633","journal-title":"Br J Anaesth"},{"key":"ref=18","first-page":"243","volume":"15","author":"Tatsuno J.","year":"1986","unstructured":"Tatsuno J.; Komatsu T.; Iida S.; Pharmacokinetic studies of argipidine (MD-805) - protein binding and blood cell binding. Jap Pharmacol Therap 1986,15(Suppl.),243-249","journal-title":"Jap Pharmacol Therap"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1592\/phco.20.4.318.34881","volume":"20","author":"Swan S.K.","year":"2000","unstructured":"Swan S.K.; Hursting M.J.; The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000,20(3),318-329","journal-title":"Pharmacotherapy"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/CCM.0b013e3181932394","volume":"37","author":"Link A.","year":"2009","unstructured":"Link A.; Girndt M.; Selejan S.; Mathes A.; B\u00f6hm M.; Rensing H.; Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med 2009,37(1),105-110","journal-title":"Crit Care Med"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/0003-4975(94)91359-5","volume":"57","author":"Staples M.H.","year":"1994","unstructured":"Staples M.H.; Dunton R.F.; Karlson K.J.; Leonardi H.K.; Berger R.L.; Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping. Ann Thorac Surg 1994,57(5),1211-1216","journal-title":"Ann Thorac Surg"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/bja\/88.4.467","volume":"88","author":"Anderson J.A.M.","year":"2002","unstructured":"Anderson J.A.M.; Saenko E.L.; Heparin resistance. Br J Anaesth 2002,88(4),467-469","journal-title":"Br J Anaesth"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10354-011-0878-6","volume":"161","author":"Fries D.","year":"2011","unstructured":"Fries D.; Thrombosis prophylaxis in critically ill patients. Wien Med Wochenschr 2011,161(3-4),68-72","journal-title":"Wien Med Wochenschr"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1191\/0267659106pf855oa","volume":"21","author":"Chan T.","year":"2006","unstructured":"Chan T.; Hwang N.C.; Lim C.H.; A statistical analysis of factors predisposing patients to heparin resistance. Perfusion 2006,21(2),99-103","journal-title":"Perfusion"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/cc9358","volume":"15","author":"Oudemans-van Straaten H.M.","year":"2011","unstructured":"Oudemans-van Straaten H.M.; Kellum J.A.; Bellomo R.; Clinical review: Anticoagulation for continuous renal replacement therapy--heparin or citrate? Crit Care 2011,15(1),202","journal-title":"Crit Care"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1055\/s-0037-1617187","volume":"28","author":"Alban S.","year":"2008","unstructured":"Alban S.; Pharmakologie der Heparine und der direkten Antikoagulanzien. Hamostaseologie 2008,28(5),400-420","journal-title":"Hamostaseologie"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1536\/ihj.50.111","volume":"50","author":"Kaku B.","year":"2009","unstructured":"Kaku B.; Katsuda S.; Taguchi T.; Nitta Y.; Hiraiwa Y.; A case of acute myocardial infarction with repetitive stent thrombosis during emergent percutaneous coronary intervention. Transient decrease in antithrombin III activity and heparin resistance. Int Heart J 2009,50(1),111-119","journal-title":"Int Heart J"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1051\/ject\/200537303","volume":"37","author":"Mejak B.","year":"2005","unstructured":"Mejak B.; Giacomuzzi C.; Shen I.; Boshkov L.; Ungerleider R.; Cardiopulmonary bypass using argatroban as an anticoagulant for a 6.0-kg pediatric patient. J Extra Corpor Technol 2005,37(3),303-305","journal-title":"J Extra Corpor Technol"},{"key":"ref=29","first-page":"42","volume":"2","author":"Kozek-Langenecker S.","year":"2014","unstructured":"Kozek-Langenecker S.; Fries D.; G\u00fctl M.; Klinischer Erfahrungsaustausch f\u00fcr die Praxis: Argatroban bei Heparinunvertr\u00e4glichkeit. Wiener Klinisches Magazin 2014,2,42-45","journal-title":"Wiener Klinisches Magazin"},{"key":"ref=30","author":"Baxalta Innovations Gmb H.","unstructured":"Baxalta Innovations Gmb H.; Veyvondi Summary of Product Characteristics","journal-title":"Veyvondi Summary of Product Characteristics"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/rth2.12064","volume":"2","author":"Keesler D.A.","year":"2017","unstructured":"Keesler D.A.; Flood V.H.; Current issues in diagnosis and treatment of von Willebrand disease. Res Pract Thromb Haemost 2017,2(1),34-41","journal-title":"Res Pract Thromb Haemost"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.2147\/CIA.S136931","volume":"13","author":"Chapin J.","year":"2018","unstructured":"Chapin J.; Von Willebrand disease in the elderly: Clinical perspectives. Clin Interv Aging 2018,13,1531-1541","journal-title":"Clin Interv Aging"},{"key":"ref=33","unstructured":""},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","volume":"10","author":"Knoebl P.","year":"2012","unstructured":"Knoebl P.; Marco P.; Baudo F.; Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012,10(4),622-631","journal-title":"J Thromb Haemost"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1160\/TH13-05-0363","volume":"110","author":"Franchini M.","year":"2013","unstructured":"Franchini M.; Mannucci P.M.; Acquired haemophilia A: A 2013 update. Thromb Haemost 2013,110(6),1114-1120","journal-title":"Thromb Haemost"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/ajh.24777","volume":"92","author":"Kruse-Jarres R.","year":"2017","unstructured":"Kruse-Jarres R.; Kempton C.L.; Baudo F.; Acquired hemophilia A: Updated review of evidence and treatment guidance. Am J Hematol 2017,92(7),695-705","journal-title":"Am J Hematol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1080\/10245332.2017.1319115","volume":"22","author":"Franchini M.","year":"2017","unstructured":"Franchini M.; Vaglio S.; Marano G.; Acquired hemophilia A: A review of recent data and new therapeutic options. Hematology 2017,22(9),514-520","journal-title":"Hematology"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1160\/TH14-12-1062","volume":"114","author":"Batty P.","year":"2015","unstructured":"Batty P.; Moore G.W.; Platton S.; Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A. Thromb Haemost 2015,114(4),804-811","journal-title":"Thromb Haemost"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/hae.12627","volume":"21","author":"Kruse-Jarres R.","year":"2015","unstructured":"Kruse-Jarres R.; St-Louis J.; Greist A.; Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia 2015,21(2),162-170","journal-title":"Haemophilia"},{"key":"ref=40","unstructured":"Standing Committee on Education and Professional Development of the Section and Board of Anaesthesiology European Trainng Requirement ETR in Anaesthesiology","journal-title":"European Trainng Requirement ETR in Anaesthesiology"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1053\/j.seminhematol.2014.02.001","volume":"51","author":"Kozek-Langenecker S.A.","year":"2014","unstructured":"Kozek-Langenecker S.A.; Perioperative management issues of direct oral anticoagulants. Semin Hematol 2014,51(2),112-120","journal-title":"Semin Hematol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.bja.2017.11.082","volume":"120","author":"Eikelboom J.W.","year":"2018","unstructured":"Eikelboom J.W.; Kozek-Langenecker S.; Exadaktylos A.; Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. Br J Anaesth 2018,120(4),645-656","journal-title":"Br J Anaesth"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","volume":"121","author":"Schiele F.","year":"2013","unstructured":"Schiele F.; van Ryn J.; Canada K.; A specific antidote for dabigatran: Functional and structural characterization. Blood 2013,121(18),3554-3562","journal-title":"Blood"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S0140-6736(15)60732-2","volume":"386","author":"Glund S.","year":"2015","unstructured":"Glund S.; Stangier J.; Schmohl M.; Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: A randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015,386(9994),680-690","journal-title":"Lancet"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.jacc.2016.01.043","volume":"67","author":"Glund S.","year":"2016","unstructured":"Glund S.; Stangier J.; van Ryn J.; Restarting dabigatran etexilate 24 h after reversal with idarucizumab and redosing idarucizumab in healthy volunteers. J Am Coll Cardiol 2016,67(13),1654-1656","journal-title":"J Am Coll Cardiol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1160\/TH16-05-0385","volume":"117","author":"Schmohl M.","year":"2017","unstructured":"Schmohl M.; Glund S.; Harada A.; Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers. Thromb Haemost 2017,117(2),269-276","journal-title":"Thromb Haemost"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJMoa1707278","volume":"377","author":"Pollack C.V.","year":"2017","unstructured":"Pollack C.V.; Reilly P.A.; van Ryn J.; Idarucizumab for dabigatran reversalefull cohort analysis. N Engl J Med 2017,377(5),431-441","journal-title":"N Engl J Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1160\/TH14-12-1080","volume":"113","author":"Glund S.","year":"2015","unstructured":"Glund S.; Moschetti V.; Norris S.; A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015,113(5),943-951","journal-title":"Thromb Haemost"},{"key":"ref=49","unstructured":"Boehringer Ingelheim International GmbH. Praxbind Summary of Product Characteristics https:\/\/www.ema.europa.eu\/documents\/product-information\/praxbind-epar-product-information_en.pdf"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1161\/CIRCULATIONAHA.115.019628","volume":"132","author":"Eikelboom J.W.","year":"2015","unstructured":"Eikelboom J.W.; Quinlan D.J.; van Ryn J.; Weitz J.I.; Idarucizumab: the antidote for reversal of dabigatran. Circulation 2015,132(25),2412-2422","journal-title":"Circulation"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","volume":"375","author":"Connolly S.J.","year":"2016","unstructured":"Connolly S.J.; Milling T.J.; Eikelboom J.W.; Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016,375(12),1131-1141","journal-title":"N Engl J Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3810\/pgm.2014.11.2829","volume":"126","author":"Costin J.","year":"2014","unstructured":"Costin J.; Ansell J.; Laulicht B.; Bakhru S.; Steiner S.; Reversal agents in development for the new oral anticoagulants. Postgrad Med 2014,126(7),19-24","journal-title":"Postgrad Med"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13049-015-0165-4","volume":"23","author":"Ponschab M.","year":"2015","unstructured":"Ponschab M.; Voelckel W.; Pavelka M.; Schlimp C.J.; Sch\u00f6chl H.; Effect of coagulation factor concentrate administration on ROTEM parameters in major trauma. Scand J Trauma Resusc Emerg Med 2015,23,84","journal-title":"Scand J Trauma Resusc Emerg Med"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/173319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T02:50:21Z","timestamp":1695005421000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/173319\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,13]]},"references-count":53,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2019,9,13]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666190708183127","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9,13]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}